Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment
BACKGROUND: Paclitaxel (PTX) is touted as an essential medicine due to its extensive use as a chemotherapeutic agent for various cancers and an antiproliferative agent for endovascular applications. Emerging studies in cardio-oncology implicate various vascular complications of chemotherapeutic agents.
METHODS: We evaluated the inflammatory response induced by the systemic administration of PTX. The investigation included RNAseq analysis of primary human endothelial cells (ECs) treated with PTX to identify transcriptional changes in pro-inflammatory mediators. Additionally, we used dexamethasone (DEX), a well-known antiinflammatory compound, to assess its effectiveness in counteracting these PTX-induced changes. Further, we studied the effects of PTX on monocyte chemoattractant protein-1 (MCP-1) levels in the media of ECs. The study also extended to in vivo analysis, where a group of mice was injected with PTX and subsequently harvested at different times to assess the immediate and delayed effects of PTX on inflammatory mediators in blood and aortic ECs.
RESULTS: Our RNAseq analysis revealed that PTX treatment led to significant transcriptional perturbations in pro-inflammatory mediators such as MCP-1 and CD137 within primary human ECs. These changes were effectively abrogated when DEX was administered. In vitro experiments showed a marked increase in MCP-1 levels in EC media following PTX treatment, which returned to baseline upon treatment with DEX. In vivo, we observed a threefold increase in MCP-1 levels in blood and aortic ECs 12 h post-PTX administration. Similar trends were noted for CD137 and other downstream mediators like tissue factor, vascular cell adhesion molecule 1, and E-selectin in aortic ECs.
CONCLUSION: Our findings illustrate that PTX exposure induces an upregulation of atherothrombotic mediators, which can be alleviated with concurrent administration of DEX. Considering these observations, further long-term investigations should focus on understanding the systemic implications associated with PTX-based therapies and explore the clinical relevance of DEX in mitigating such risks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Vascular medicine (London, England) - (2024) vom: 16. Apr., Seite 1358863X241231942 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Mengwei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dexamethasone |
|---|
| Anmerkungen: |
Date Revised 16.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1177/1358863X241231942 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371127556 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371127556 | ||
| 003 | DE-627 | ||
| 005 | 20240416233708.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1358863X241231942 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM371127556 | ||
| 035 | |a (NLM)38623630 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Mengwei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alleviating iatrogenic effects of paclitaxel via antiinflammatory treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a BACKGROUND: Paclitaxel (PTX) is touted as an essential medicine due to its extensive use as a chemotherapeutic agent for various cancers and an antiproliferative agent for endovascular applications. Emerging studies in cardio-oncology implicate various vascular complications of chemotherapeutic agents | ||
| 520 | |a METHODS: We evaluated the inflammatory response induced by the systemic administration of PTX. The investigation included RNAseq analysis of primary human endothelial cells (ECs) treated with PTX to identify transcriptional changes in pro-inflammatory mediators. Additionally, we used dexamethasone (DEX), a well-known antiinflammatory compound, to assess its effectiveness in counteracting these PTX-induced changes. Further, we studied the effects of PTX on monocyte chemoattractant protein-1 (MCP-1) levels in the media of ECs. The study also extended to in vivo analysis, where a group of mice was injected with PTX and subsequently harvested at different times to assess the immediate and delayed effects of PTX on inflammatory mediators in blood and aortic ECs | ||
| 520 | |a RESULTS: Our RNAseq analysis revealed that PTX treatment led to significant transcriptional perturbations in pro-inflammatory mediators such as MCP-1 and CD137 within primary human ECs. These changes were effectively abrogated when DEX was administered. In vitro experiments showed a marked increase in MCP-1 levels in EC media following PTX treatment, which returned to baseline upon treatment with DEX. In vivo, we observed a threefold increase in MCP-1 levels in blood and aortic ECs 12 h post-PTX administration. Similar trends were noted for CD137 and other downstream mediators like tissue factor, vascular cell adhesion molecule 1, and E-selectin in aortic ECs | ||
| 520 | |a CONCLUSION: Our findings illustrate that PTX exposure induces an upregulation of atherothrombotic mediators, which can be alleviated with concurrent administration of DEX. Considering these observations, further long-term investigations should focus on understanding the systemic implications associated with PTX-based therapies and explore the clinical relevance of DEX in mitigating such risks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a drug-coated balloon | |
| 650 | 4 | |a endovascular therapy | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a paclitaxel | |
| 650 | 4 | |a peripheral artery disease (PAD) | |
| 700 | 1 | |a Lotfollahzadeh, Saran |e verfasserin |4 aut | |
| 700 | 1 | |a Elzinad, Nagla |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiaosheng |e verfasserin |4 aut | |
| 700 | 1 | |a Elsadawi, Murad |e verfasserin |4 aut | |
| 700 | 1 | |a Gower, Adam C |e verfasserin |4 aut | |
| 700 | 1 | |a Belghasem, Mostafa |e verfasserin |4 aut | |
| 700 | 1 | |a Shazly, Tarek |e verfasserin |4 aut | |
| 700 | 1 | |a Kolachalama, Vijaya B |e verfasserin |4 aut | |
| 700 | 1 | |a Chitalia, Vipul C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vascular medicine (London, England) |d 1996 |g (2024) vom: 16. Apr., Seite 1358863X241231942 |w (DE-627)NLM094881766 |x 1477-0377 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:04 |g pages:1358863X241231942 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1358863X241231942 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 04 |h 1358863X241231942 | ||